Inhibitors of histone deacetylases as anti-inflammatory drugs.
This review addresses the issue of histone deacetylase (HDAC) inhibitors as developed for the treatment of cancer and for the investigation of the inhibition of inflammation. The review focuses on both in vitro and in vivo models of inflammation and autoimmunity. Of particular interest is the inhibition of pro-inflammatory cytokines. Although the reduction in cytokines appears paradoxical at first, upon examination, some genes that are anti-inflammatory are upregulated by inhibition of HDAC. Whether skin diseases will be affected by inhibitors of HDAC remains to be tested.
Dinarello
C A
CA
University of Colorado Health Sciences Center, Denver 80262, USA. cdinare333@aol.com
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000276:immunology / Q000627:therapeutic use; D003208:Concanavalin A / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D004195:Disease Models, Animal; D004791:Enzyme Inhibitors / Q000276:immunology / Q000627:therapeutic use*; D005814:Genes, Viral; D006086:Graft vs Host Disease / Q000276:immunology; D006505:Hepatitis / Q000276:immunology; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D007375:Interleukin-1 / Q000276:immunology; D008070:Lipopolysaccharides / Q000276:immunology
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D016207:Cytokines; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D007375:Interleukin-1; D008070:Lipopolysaccharides; D003208:Concanavalin A; D006655:Histone Deacetylases